Home > Healthcare > Pharmaceuticals > Finished Drug Form > Plasma Derived Therapy Market

Plasma Derived Therapy Market Share

Report ID: GMI5271
Published Date: Nov 2023
Report Format: PDF

Download Free Sample

Plasma Derived Therapy Market Share

Some of the prominent business players operating in the plasma derived therapy industry include CSL Behring, Takeda Pharmaceutical Company Limited, Biotest AG, Octapharma, BPL, ADMA Biologics, Grifols, SA, Kedrion, Kamada Pharmaceuticals, SK Plasma, Pfizer, among others. These market players are adopting various inorganic growth strategies to gain market share and sustainable competitive advantage.

Market players operating in the plasma derived therapy is as mentioned below:

CSL Behring
Takeda Pharmaceutical Company Limited.
Biotest AG
Octapharma
BPL
ADMA Biologics
Grifols, SA
Kedrion
Kamada Pharmaceuticals
SK Plasma
Pfizer, Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Plasma derived therapy industry size exceeded USD 16.8 billion in 2022 and is set to expand at 7.5% CAGR from 2023-2032 owing to the rising prevalence of rare diseases including primary immunodeficiency diseases, idiopathic thrombocytopenic purpura (ITP), and von Willebrand disease.

Plasma derived therapy industry from the immunoglobulin segment accounted for 48.1% revenue share in 2022 and is estimated to exhibit steady growth through 2032 attributed to the increasing usage for the treatment of several complex diseases globally.

North America held over 52.2% revenue share of the plasma derived therapy industry in 2022 and is estimated to expand at a robust CAGR through 2032 driven by favorable government initiatives and the growing awareness about plasma-derived therapies among blood donors.

Few leading plasma derived therapy industry players are CSL Behring, Takeda Pharmaceutical Company Limited, Biotest AG, Octapharma, BPL, ADMA Biologics, Grifols, SA, Kamada Pharmaceuticals, SK Plasma